



Express Mail No.: EV 841 454 793 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ternansky et al.

Confirmation No.: 9257

Application No.: 10/723,144

Group Art Unit: 1654

Filed: November 25, 2003

Examiner: Cordero Garcia, Marcela M.

For: PEPTIDES WHICH INHIBIT ANGIOGENESIS,
CELL MIGRATION, CELL INVASION AND CELL
PROLIFERATION, COMPOSITIONS AND USES
THEREOF

Attorney Docket No.: 9715-023-999
(formerly: 34433/US/3/AMP/S)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the United States Patent and Trademark Office (“USPTO”) of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner’s attention to references A20-A22 and C77-C113 listed on the attached form entitled “List of References Cited by Applicant.”

Copies of references C77-C113 are submitted herewith. Copies of references A20-A22 are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as “prior art” against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(4), Applicants believe that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 11, 2006

Adriane M. Antler^{32,605}
Adriane M. Antler (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosure

AUG 11 2006



LIST OF REFERENCES CITED BY APPLICANT
 (Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
9715-023-999	10/723,144
APPLICANT	
Ternansky et al.	
FILING DATE	ART UNIT
November 25, 2003	1654

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A20	6,225,284	05/01/01	Albert et al.	
	A21	US 2002/0151501	10/17/02	Bowers et al.	
	A22	US 2005/0020810	01/27/05	Ternansky et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C77	ABOAGYE et al., "Use of positron emission tomography in anticancer drug development," Invest. New Drugs 2003, 21(2):169-181.	
	C78	AKIYAMA et al., "Fibronectin and integrins in invasion and metastasis," Cancer Metastasis Rev. 1995, 14(3):173-189.	
	C79	BOKEL, "Integrins in development: moving on, responding to, and sticking to the extracellular matrix," Dev. Cell, 2002, 3(3):311-321.	
	C80	BORNSTEIN et al., "Matricellular proteins: extracellular modulators of cell function," Curr. Opin. Cell Biol. 2002, 14(5):608-616.	
	C81	COOPER et al., "The role of alpha(v)beta(3) in prostate cancer progression," Neoplasia 2002, 4(3): 191-194.	
	C82	DAMIANO, "Integrins as novel drug targets for overcoming innate drug resistance," Curr. Cancer Drug Targets 2002, 2(1):37-43.	
	C83	FELDING-HABERMANN, "Integrin adhesion receptors in tumor metastasis," Clin. Exp. Metastasis 2003, 20(3): 203-213.	
	C84	FELDING-HABERMANN, "Integrin activation controls metastasis in human breast cancer," Proc. Natl. Acad. Sci. USA 2001, 98(4):1853-1858.	
	C85	GEIGER et al., "Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk," Nat. Rev. Mol. Cell Biol. 2001, 2(11):793-805.	
	C86	GLASER et al., "Applications of positron-emitting halogens in PET oncology," Int. J. Oncol. 2003, 22(2):253-267.	
	C87	HERSCHMAN, "Molecular Imaging: Looking at Problems, Seeing Solutions," Science 2003, 302(5645): 605-608.	
	C88	HOOD et al., "Role of integrins in cell invasion and migration," Nat. Rev. Cancer 2002, 2(2): 91-100	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9715-023-999	10/723,144
	APPLICANT	
	Ternansky et al.	
	FILING DATE	ART UNIT
	November 25, 2003	1654

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
C89	KEMPERMAN et al., "The role of integrins and integrin activation in liver metastasis," Invasion Metastasis 1994-95, 14(1-6):98-108.	
C90	KERR et al., "The alpha v integrin antagonists as novel anticancer agents: an update," Expert Opin. Investig. Drugs 2002, 11(12):1765-1774.	
C91	KIM et al., "Regulation of Angiogenesis in Vivo by Ligation of Integrin 5B1 with the Central Cell-Binding Domain of Fibronectin," Am. J. Pathol. 2000, 156(4):1345-1362.	
C92	KUMAR, "Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis," Curr. Drug Targets 2003, 4(2):123-131.	
C93	LABAT-ROBERT, "Fibronectin in Malignancy," Semin. Cancer Biol. 2002, 12(3):187-195.	
C94	LI et al., "Synthesis of polyethylene glycol (PEG) derivatives and PEGylated-peptide biopolymer conjugates," Biomacromolecules 2003, 4:1055-1067.	
C95	LIU et al., "Antiangiogenic therapy," Semin. Oncol. 2002, 29(3 Suppl. 11): 96-103.	
C96	LIVANT et al. "Anti-invasive, Antitumorigenic, and Antimetastatic Activities of the PHSCN Sequence in Prostate Carcinoma," Cancer Res. 2000, 60(2): 309-320.	
C97	LOHR et al., "Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas," Pancreas 1996, 12(3):248-259.	
C98	MERAJVER et al., "Cooper Depletion as and Anti-Angiogenic Strategy in HER2-neu Transgenic," Proceedings of Special AACR Conference on Angiogenesis and Cancer 1998, Abstract #B-11, January 22-24.	
C99	METZNER et al., "Evidence of the involvement of phosphatidylinositol 3-kinase in the migration, actin stress fiber formation, and alpha v beta 3-integrin- mediated adherence of human melanoma cells," J. Invest. Dermatol. 1996, 107(4): 597-602.	
C100	NIP et al., "The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis," Cancer Metastasis Rev. 1995, 14(3): 241-252.	
C101	O'BRIEN et al., "Expression of the integrin alpha 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation," Exp. Cell Res. 1996, 224(1): 208-213.	
C102	PECHEUR et al., "Integrin alpha v beta 3 expression confers on tumor cells a greater propensity to metastasize to bone," FASEB J. 2002, 16(10): 1266-1268.	
C103	PLATTEN et al., "Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression," Biochem. Biophys. Commun. 2000, 268(2): 607-611.	
C104	RABB et al., "Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney," Am. J. Nephrol. 1996, 16(5):402-408.	
C105	RALEIGH et al., "Pharmacokinetics of Isotrentino (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," British J. Cancer, 1999, 80, Suppl. 2, 96.	
C106	RUOSLAHTI, "Fibronectin and its alpha 5 beta 1 integrin receptor in malignancy," Invasion Metastasis 1994; 14(1-6): 87-97.	
C107	RUST et al., "The Promise of Integrins as Effective Targets for Anticancer Agents," J. Biomed. Biotechnol. 2002, 2(3): 124-130.	
C108	STOELTZING et al., "Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice," Int. J. Cancer 2003, 104(4):496-503.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9715-023-999	10/723,144
	APPLICANT Ternansky et al.	
	FILING DATE November 25, 2003	ART UNIT 1654

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
C109	STUPACK et al., "Get a ligand, get a life: integrins, signaling and cell survival," J. Cell Sci. 2002, 115: 3729-38.	
C110	TANI et al., "Expression level of integrin alpha 5 on tumor cells affects the rate of metastasis to the kidney," Br. J. Cancer 2003, 88(2): 327-333.	
C111	TUCKER, "Inhibitors of integrins," Curr. Opin. Pharmacol. 2002, 2(4): 394-402.	
C112	VAN DE WIELE et al., "Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging," Eur. J. Nucl. Med. Mol. Imaging 2002, 29(5): 699-709.	
C113	VARNER et al., "Tumor angiogenesis and the role of vascular cell integrin alphavbeta3," Import Adv. Oncol. 1996, 69-87.	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD-1632353v1